ClinicalTrials.gg
Not yet recruitingNCT07297693Updated Dec 22, 2025

A Study to Evaluate the Pharmacokinetics and Safety Between HIP2503 and HCP1306 in Healthy Volunteers

A Phase 1 interventional study of HIP2503 and HCP1306 in Healthy, sponsored by Hanmi Pharmaceutical Company Limited. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
19 Years to 64 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HIP2503 and HCP1306 in healthy volunteers.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Hanmi Pharmaceutical Company Limited is the lead sponsor of 191 studies on the registry; 12 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 19\~64 years in healthy volunteers
  • 18 kg/m\^2 ≤ ≤ 30 kg/m\^2, weight(men) ≥55kg / weight(women) ≥45kg
  • Agrees that the person, spouse, or partner uses appropriate medically recognized and does not provide sperm or eggs from the date of administration of the first drug to 14 days after the administration of the last investigational drug
  • Subjects who voluntarily decides to participate in this clinical trial and agree in writing to ensure compliance with the clinical trial

Exclusion criteria

Exclusion Criteria:

  • Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study
  • Subjects who judged ineligible by the investigator
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Arm 1

    * Period1 : HCP1306 * Period2 : HIP2503

    Drug: HIP2503 · Drug: HCP1306

  • Experimental
    Arm 2

    * Period 1 : HIP2503 * Period 2 : HCP1306

    Drug: HIP2503 · Drug: HCP1306

Interventions

  • DrugHIP2503

    Take 1 orally disintegrating tablet once per period

  • Take 1 tablet once per period

06

What researchers measure

Primary outcomes

  1. AUCt

    Pharmacokinetic evaluation

    Time frame: 0~72 hours

  2. Cmax

    Pharmacokinetic evaluation

    Time frame: 0~72 hours

Secondary outcomes

  1. Ka

    Pharmacokinetic evaluation

    Time frame: 0~72 hours

  2. Concentration/Cmax_%

    Pharmacokinetic evaluation

    Time frame: 0~72 hours

  3. AUCinf

    Pharmacokinetic evaluation

    Time frame: 0~72 hours

  4. AUCt/AUCinf

    Pharmacokinetic evaluation

    Time frame: 0~72 hours

  5. Tmax

    Pharmacokinetic evaluation

    Time frame: 0~72 hours

  6. t1/2

    Pharmacokinetic evaluation

    Time frame: 0~72 hours

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Mar 2026, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Dec 22, 2025
StartEst.
Dec 19, 2025
Primary completionEst.
Mar 25, 2026
CompletionEst.
Apr 10, 2026
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07297693
Responsible party
Sponsor
First posted
Dec 22, 2025
Start date
Dec 19, 2025 (estimated)
Primary completion
Mar 25, 2026 (estimated)
Completion
Apr 10, 2026 (estimated)
Last update
Dec 22, 2025

Study contacts

Jee Won Shon
Contact
jeewon.shon@hanmi.co.kr
+82-2-410-9037
Hee Ju Hong
principal investigator · H Plus Yangji Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HCP1306

Start the discussion